Lepu Medical and Shandong Buchang Pharma were among the limited partners that have backed the healthcare investor's latest fund.

Novo and Takeda are set to exit antibody therapy developer Symphogen in an acquisition by one of its strategic partners, Servier.

Cedars-Sinai Medical Center contributed to a round for the stealth-stage diagnostics technology developer, which raised $101m less than a year ago.

SAIC Motor fund Hengxu Investment and a Sinopharm-backed joint venture were among the investors in a $66.3m round for the RNA drug developer.

The Pharamron-backed oncology drug developer floated at the top of its range while increasing the number of shares in the offering.

Lilly Asia Ventures and Johnson & Johnson Innovation – JJDC are both investing in a series A round for the cell therapy developer, a spinoff from Genscript Biotech.

The UCL and Ludwig Institute for Cancer Research spinout has collected $125m from investors including existing shareholder Vives Louvain Technology Fund.

Undisclosed pharmaceutical companies were among the investors in the venture firm's third fund, which will target biopharmaceutical developers.

Posco Capital was among the participants as Cytovant, an Asia-focused spinoff from Roivant Sciences, secured $23.5m a year after it was launched.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.